Enabling innovation for a better world

Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that it has entered into a collaboration, exclusive option and license agreement with AstraZeneca to develop, manufacture and commercialise autologous, engineered Treg cell therapies for two autoimmune disease indications.

For 30 years, UCLB has been supporting and developing innovations that emerge from the world-leading research at UCL. Find out more about our work over the years, and what the future holds.

In the fifth episode of this podcast series, Marina Santilli, UCLB Associate Director, Engineering & Physical Sciences is in conversation with Dr. Daniel Hulme, CEO and Founder of Satalia.

The global demand for targeted, effective treatments for a wide range of diseases has led to significant growth in the number of antibody drugs. A third of all new medicines under development involve an antibody therapy. They account for more than 100 licensed treatments for cancer, autoimmune disease and blood clotting, and over 200 were in development during the COVID-19 pandemic to tackle the virus.